This HTML5 document contains 74 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n7http://linked.opendata.cz/resource/drugbank/drug/DB00614/identifier/chebi/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n23http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n8http://linked.opendata.cz/resource/drugbank/company/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00614/identifier/wikipedia/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00614/identifier/pharmgkb/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00614/identifier/kegg-compound/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00614/identifier/pubchem-compound/
n21http://bio2rdf.org/drugbank:
n27http://www.drugs.com/cons/
admshttp://www.w3.org/ns/adms#
n17http://linked.opendata.cz/resource/drugbank/drug/DB00614/identifier/pubchem-substance/
n9http://linked.opendata.cz/resource/drugbank/drug/DB00614/identifier/kegg-drug/
n6http://linked.opendata.cz/resource/drugbank/drug/DB00614/identifier/drugbank/
n20http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n26http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n22http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n25http://www.rxlist.com/cgi/generic2/
n10http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n5http://linked.opendata.cz/resource/drugbank/drug/DB00614/identifier/chemspider/
n12http://linked.opendata.cz/resource/atc/
n11http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00614
rdf:type
n3:Drug
n3:description
A nitrofuran derivative with antiprotozoal and antibacterial activity. Furazolidone binds bacterial DNA which leads to the gradual inhibition of monoamine oxidase. (From Martindale, The Extra Pharmacopoeia, 30th ed, p514)
n3:group
approved
n3:halfLife
10 minutes
n3:indication
For the specific and symptomatic treatment of bacterial or protozoal diarrhea and enteritis caused by susceptible organisms.
n3:manufacturer
n8:271B56A0-363D-11E5-9242-09173F13E4C5
owl:sameAs
n20:DB00614 n21:DB00614
dcterms:title
Furazolidone
adms:identifier
n5:3317 n6:DB00614 n7:5195 n9:D00830 n14:C07999 n15:PA164746760 n16:5323714 n17:46507291 n18:Furazolidone
n3:mechanismOfAction
Furazolidone and its related free radical products are believed to bind DNA and induce cross-links. Bacterial DNA is particularly susceptible to this drug leading to high levels of mutations (transitions and transversions) in the bacterial chromosome.
n3:packager
n8:271B569F-363D-11E5-9242-09173F13E4C5
n3:synonym
N-(5-Nitro-2-furfurylidene)-3-amino-2-oxazolidone N-(5-Nitro-2-furfurylidene)-3-aminooxazolidine-2-one Nitrofurazolidone Furazolidone FZL Nitrofurazolidonum 3-[(5-Nitrofurylidene)amino]-2-oxazolidone 3-[(5-Nitrofurfurylidene)amino]-2-oxazolidinone 5-Nitro-N-(2-oxo-3-oxazolidinyl)-2-furanmethanimine Furazolidonum Furoxone 3-[(5-Nitrofurfurylidene)amino]-2-oxazolidone 3-{[(5-nitro-2-furanyl)methylene]amino}-2-oxazolidinone Furazolidona 3-(5'-Nitrofurfuralamino)-2-oxazolidone
n3:toxicity
Reactions to Furoxone have been reported including a fall in blood pressure, urticaria, fever, arthralgia, and a vesicular morbilliform rash. Other adverse effects can include a brown discoloration of the urine; hemolysis can occur in G6PDH-deficient patients. The drug has a monoamine oxidase (MAO) inhibitory effect and should never be given concurrently to individuals already taking MAO inhibitors.
n3:synthesisReference
Drake, G.D., Gever, G. and Hayes, K.J.; U.S. Patent 2,759,931; August 21, 1956; assigned to The Norwich Pharmacal Company. Gever, G. and O'Keefe, C.J.; U.S. Patent 2,927,l IO; March 1, 1960; assigned to The Norwich Pharmacal Company.
n22:hasConcept
n23:M0008899
foaf:page
n25:furazol.htm n27:furazolidone.html
n3:IUPAC-Name
n10:271B56A6-363D-11E5-9242-09173F13E4C5
n3:InChI
n10:271B56AC-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n10:271B56AB-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n10:271B56A8-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n10:271B56A9-363D-11E5-9242-09173F13E4C5
n3:SMILES
n10:271B56AA-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n10:271B56A4-363D-11E5-9242-09173F13E4C5 n10:271B56BB-363D-11E5-9242-09173F13E4C5
n3:logP
n10:271B56A5-363D-11E5-9242-09173F13E4C5 n10:271B56A2-363D-11E5-9242-09173F13E4C5 n10:271B56BD-363D-11E5-9242-09173F13E4C5
n3:logS
n10:271B56A3-363D-11E5-9242-09173F13E4C5
n11:hasATCCode
n12:G01AX06
n3:H-Bond-Acceptor-Count
n10:271B56B2-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n10:271B56B3-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n10:271B56AD-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n10:271B56AE-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n10:271B56B0-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n10:271B56AF-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n10:271B56B1-363D-11E5-9242-09173F13E4C5
n3:absorption
Radiolabeled drug studies indicate that furazolidone is well absorbed following oral administration
n3:affectedOrganism
Microbes (bacteria, parasites)
n3:casRegistryNumber
67-45-8
n3:category
n3:containedIn
n26:271B56A1-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n10:271B56B7-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n10:271B56B9-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n10:271B56BA-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n10:271B56BC-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n10:271B56B6-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n10:271B56B5-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n10:271B56B8-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n10:271B56A7-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n10:271B56B4-363D-11E5-9242-09173F13E4C5